MethylGene Inc. (TSX:MYG) is a publicly-traded, clinical stage, biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer. The Company's product candidates include:

MGCD265,  an oral, multi-targeted kinase inhibitor targeting the c-Met, VEGF1, VEGF2, VEGF3, Ron and Tie-2 receptor tyrosine kinases. MGCD265 is currently being evaluated in two Phase I clinical trials (Trials 101 and 102) in patients with solid tumors, and in the first stage of a Phase II program (Trial 103). Trial 103 is to determine the maximum tolerated dose of MGCD265 in combination with docetaxel or erlotinib in preparation for the randomized second stage of the trial in non-small cell lung cancer patients (Trial 104).

MGCD290, a fungal Hos2 inhibitor used in combination with azoles for fungal infections. The Company has completed enrollment for the Phase I program with a total of 120 healthy volunteers. The study included 14 days of continuous oral dosing with MGCD290 in combination with fluconazole, an approved agent commonly used to combat fungal infections.

Mocetinostat (MGCD0103), an oral, isotype-selective histone deacetylase inhibitor which has been in multiple clinical trials for solid tumors and hematological malignancies. The Company is continuing the Phase II clinical trial (Trial 008) evaluating mocetinostat in patients with relapsed or refractory follicular lymphoma who have had three or more prior therapies.

MethylGene's development and commercialization partners include Taiho Pharmaceutical, Otsuka Pharmaceutical and EnVivo Pharmaceuticals.

MethylGene develops drugs that specifically target enzymes that are involved in certain diseases such as cancer. We do this by understanding the characteristics of the enzyme involved in the disease and then creating a molecule that will specifically inhibit that enzyme from functioning. In this way, the enzyme may be controlled. Molecules that have the desired profile become clinical candidates and are eventually tested in human clinical trials.

The advantage of having drugs that are specific to their target is that they should only affect diseased cells leaving healthy cells untouched. This is in contrast to other approaches such as chemotherapy or radiation therapy where both healthy and diseased cells are affected causing unnecessary side effects.

Our strength is in our ability to discover, to develop, and deliver target-specific drugs. We invite you to browse our web site to learn more about MethylGene.